| 摘要 |
Disclosed is a therapeutic composition, comprising (a) a compound that binds to PD-1 and (b) cyclophosphamide or an analogue of cyclophosphamide in a pharmaceutically acceptable carrier, wherein said compound is a fusion protein comprising first and second peptide portions, wherein said first peptide portion comprises an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin. Further disclosed is the use of the therapeutic composition in the manufacture of a medicament for the treatment of cancer or infectious disease.
|
